Share on StockTwits

United Therapeutics (NASDAQ:UTHR) COO Roger Jeffs unloaded 10,000 shares of the company’s stock in a transaction dated Friday, July 11th. The stock was sold at an average price of $93.06, for a total transaction of $930,600.00. Following the transaction, the chief operating officer now directly owns 1,234 shares in the company, valued at approximately $114,836. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of United Therapeutics (NASDAQ:UTHR) traded down 0.14% on Monday, hitting $93.13. 551,034 shares of the company’s stock traded hands. United Therapeutics has a 1-year low of $67.03 and a 1-year high of $116.65. The stock has a 50-day moving average of $92.54 and a 200-day moving average of $99.2. The company has a market cap of $4.487 billion and a P/E ratio of 20.26.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, April 29th. The company reported $1.77 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter last year, the company posted $1.19 earnings per share. United Therapeutics’s revenue was up 18.1% compared to the same quarter last year. On average, analysts predict that United Therapeutics will post $7.77 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at RBC Capital reiterated a “sector perform” rating on shares of United Therapeutics in a research note on Monday, June 16th. They now have a $90.00 price target on the stock. Separately, analysts at Credit Suisse upgraded shares of United Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, June 16th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. United Therapeutics presently has a consensus rating of “Hold” and an average price target of $97.54.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.